

**Table 2.** Coagulation variables and IGF-1 levels of investigated subjects. Mean value ( $\bar{x}$ ), standard error (SE), (Range)

	<b>Fibrinogen (g/l)</b>	<b>PT (%)</b>	<b>aPTT (s)</b>	<b>IGF-1 (nmol/L)</b>
Control group	3.3±0.1 (2.9-4.5)	104.3±1.6 (92-113)	32.4±1.4 (27.8-36.1)	21.7±1.8 (14.6-36.7)
Female	3,5±0.2 (3.0-4.5)	105.6±1.3 (95-113)	32.6±1.2 (25-36.1)	22.8±3.7 (16.1-36.7)
Male	3,2±0.5 (2.9- 4.1)	100.8±1.0 (92-111)	31.1±1.1 (27.8-33)	20.2±2.0 (14.6-26.5)
GHD (at baseline)	3.7±0.3 (2.1-6.7)	103.3±2.8 (86-128)	32.8±1.3 (18.4-42.1)	8.2±1.5† (1.9-23.5)
Female	3.8±0.3 (2.5-5.7)	107.5±4.2 (91-128)	32.7±1.3 (25.4-38.5)	10.1±2.3† (2.4-23.5)
Male	3.6±0.6 (2.1-6.7)	97.3±2.6 (86-107)	28.8±4.6 (18.4-42.1)	7.8±1.6 †(1.9-15.9)
GHD (3 months)	3.8±0.2 (2.6-5.7)	108.8±5.4 (78-181)	31.4±1.1 (23-39)	24.2±2.9** (7.9-49.3)
Female	3.9±0.3 (2.6-5.7)	114.4±8.8 (92-181)	30.9±1.4 (23-39)	28.8±4.4** (7.9-46.4)
Male	3.5±0.2 (2.7-4.6)	100.8±1.9 (89-109)	32.3±1.9 (25-38)	24.7±4.6** (10.7-49.3)
GHD (6 months)	3.6±0.2 (2.3-5.0)	117.1±6.1*† (92-166)	31.6±1.5 (22.9-41.4)	25.3±4.1** (2.6-75.0)
Female	3.7±0.3 (2.3-5.0)	120.7±9.0*† (88-166)	31.7±2.0 (22.9-40)	21.6±5.9** (2.6-75.0)
Male	3.6±0.3 (2.4-5.0)	111.9±7.5*† (89-187)	31.3±2.3 (24.1-41.4)	26.4±4.9** (8.8-33.9)
GHD (12 months)	3.7±0.1 (2.6-5.4)	126.3±9.1*† (88-212)	34.9±2.2 (25.4-50.4)	23.3±2.8** (7.0-60.1)
Female	3.7±0.3 (2.6-5.4)	133.4±11.5*† (88-212)	30.3±1.1 (25.4-34.7)	21.9±2.6** (7.0-60.1)
Male	3.8±0.2 (3.2-4.9)	108.6±4.8*† (92-127)	39.7±2.1* (31.1-50.4)	22.9±3.1** (9.9-50.3)

\* patients before vs. after therapy p<0.05, \*\* patients before vs. after therapy p<0.01, †patients vs. controls p<0.05